MDM2 and inflammatory myofibroblastic tumor: Five patients exhibited complete response (CR) or near CR as the best response to targeted therapies; double immunotherapy (N = 2) or ICI monotherapy (N = 1) for high or intermediate TMB [12,18], an MDM2 inhibitor in one patient with WDLPS [10], and larotrectinib, an NTRK inhibitor, in another patient with an inflammatory myofibroblastic tumor (IMT) harboring ETV6-NTRK3 fusion [12].